| Primary |
| Fungal Infection |
29.4% |
| Candidiasis |
13.6% |
| Ill-defined Disorder |
6.0% |
| Prophylaxis |
5.7% |
| Chronic Obstructive Pulmonary Disease |
4.7% |
| Infection |
4.1% |
| Hypertension |
3.3% |
| Vulvovaginal Mycotic Infection |
3.2% |
| Rheumatoid Arthritis |
3.0% |
| Sepsis |
2.8% |
| Systemic Candida |
2.8% |
| Oral Candidiasis |
2.7% |
| Pain |
2.7% |
| Antifungal Prophylaxis |
2.4% |
| Oesophageal Candidiasis |
2.4% |
| Atrial Fibrillation |
2.2% |
| Breast Cancer Metastatic |
2.2% |
| Diabetes Mellitus |
2.2% |
| Meningitis Cryptococcal |
2.2% |
| Osteoporosis |
2.2% |
|
| Drug Ineffective |
13.4% |
| Drug Hypersensitivity |
12.3% |
| Vomiting |
9.7% |
| Rash |
9.3% |
| Urticaria |
6.3% |
| Weight Decreased |
5.2% |
| Renal Impairment |
4.1% |
| Toxic Epidermal Necrolysis |
3.7% |
| Weight Increased |
3.7% |
| Anuria |
3.4% |
| Death |
3.4% |
| Fungal Infection |
3.4% |
| Interstitial Lung Disease |
3.4% |
| Medication Error |
3.0% |
| Stevens-johnson Syndrome |
3.0% |
| Arrhythmia |
2.6% |
| Nausea |
2.6% |
| Pseudomembranous Colitis |
2.6% |
| Skin Laceration |
2.6% |
| Drug Interaction |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
21.4% |
| Product Used For Unknown Indication |
14.2% |
| Adult T-cell Lymphoma/leukaemia |
11.0% |
| Fungal Infection |
6.8% |
| Prophylaxis |
6.8% |
| Pneumonia |
4.9% |
| Hypertension |
3.6% |
| Infection Prophylaxis |
3.3% |
| Candidiasis |
3.1% |
| Sepsis |
3.0% |
| Pain |
2.9% |
| Hiv Infection |
2.9% |
| Rheumatoid Arthritis |
2.7% |
| Antifungal Prophylaxis |
2.4% |
| Constipation |
2.1% |
| Gastrooesophageal Reflux Disease |
2.0% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Infection |
1.9% |
| Immunosuppressant Drug Therapy |
1.7% |
| Multiple Myeloma |
1.4% |
|
| Toxic Epidermal Necrolysis |
13.4% |
| Vomiting |
13.4% |
| Drug Ineffective |
8.5% |
| Thrombocytopenia |
7.0% |
| Death |
4.5% |
| Interstitial Lung Disease |
4.5% |
| Pain |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Jaundice |
4.0% |
| Renal Failure Acute |
4.0% |
| Blood Pressure Decreased |
3.5% |
| Liver Injury |
3.5% |
| Megacolon |
3.5% |
| Skin Laceration |
3.5% |
| Treatment Noncompliance |
3.5% |
| Renal Failure |
3.0% |
| Renal Impairment |
3.0% |
| Urinary Tract Infection |
3.0% |
| Urticaria |
3.0% |
| Drug Hypersensitivity |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.5% |
| Drug Use For Unknown Indication |
17.4% |
| Prophylaxis |
9.6% |
| Multiple Myeloma |
7.0% |
| Hiv Infection |
6.4% |
| Pain |
5.4% |
| Hypertension |
3.9% |
| Infection Prophylaxis |
2.7% |
| Depression |
2.4% |
| Nausea |
2.3% |
| Stem Cell Transplant |
1.8% |
| Anxiety |
1.8% |
| Diabetes Mellitus |
1.6% |
| Antifungal Prophylaxis |
1.5% |
| Rheumatoid Arthritis |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Insomnia |
1.5% |
| Pneumonia |
1.4% |
| Non-small Cell Lung Cancer |
1.4% |
| Fungal Infection |
1.4% |
|
| White Blood Cell Count Decreased |
12.4% |
| Vomiting |
11.3% |
| Weight Decreased |
9.2% |
| Thrombocytopenia |
7.7% |
| Sepsis |
7.4% |
| Pneumonia |
6.6% |
| Pyrexia |
5.4% |
| Pulmonary Embolism |
4.6% |
| Urinary Tract Infection |
4.4% |
| Weight Increased |
4.1% |
| Respiratory Failure |
3.5% |
| Pain |
3.4% |
| Type 2 Diabetes Mellitus |
2.8% |
| Death |
2.6% |
| Renal Failure Acute |
2.6% |
| Renal Failure |
2.5% |
| Septic Shock |
2.5% |
| Rash |
2.4% |
| Febrile Neutropenia |
2.3% |
| Renal Impairment |
2.3% |
|
| Interacting |
| Fungal Infection |
10.8% |
| Lyme Disease |
9.4% |
| Hypercalcaemia |
8.6% |
| Hypertension |
8.6% |
| Atrial Fibrillation |
7.9% |
| Pain |
5.0% |
| Prophylaxis |
5.0% |
| Candidiasis |
4.3% |
| Disseminated Tuberculosis |
4.3% |
| Diverticular Perforation |
4.3% |
| Gastric Sarcoma |
4.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.6% |
| Renal Transplant |
3.6% |
| Abdominal Pain |
2.9% |
| Abnormal Behaviour |
2.9% |
| Brain Neoplasm Malignant |
2.9% |
| Candida Infection |
2.9% |
| Combined Immunodeficiency |
2.9% |
| Deep Vein Thrombosis |
2.9% |
| Depression |
2.9% |
|
| Drug Interaction |
15.8% |
| Withdrawal Syndrome |
10.5% |
| Haemorrhagic Anaemia |
7.9% |
| Urinary Incontinence |
7.9% |
| Nausea |
5.3% |
| Renal Tubular Disorder |
5.3% |
| Status Epilepticus |
5.3% |
| Sudden Death |
5.3% |
| Vomiting |
5.3% |
| Weight Decreased |
5.3% |
| Clostridium Difficile Colitis |
2.6% |
| Dizziness |
2.6% |
| Electrocardiogram Qt Prolonged |
2.6% |
| Epistaxis |
2.6% |
| Hyperkalaemia |
2.6% |
| Hyperphosphataemia |
2.6% |
| Mouth Ulceration |
2.6% |
| Nephropathy Toxic |
2.6% |
| Palpitations |
2.6% |
| Pharyngeal Erythema |
2.6% |
|
